Abstract
Cardiovascular disease still remains the primary cause of death worldwide and obesity is becoming recognized as one of the most critical contributing risk factors. The increased prevalence of obesity casts a cloud over the global health and the whole societies and will still be burdened in the future. Therefore, prevention and therapy of obesity is a beneficial strategy for the prevention of chronic cardiovascular disease. Numerous studies have demonstrated that gut microbiota takes part in human health and disease including obesity. Traditional herbs hold great potential to improve people’s health and wellness, particularly in the area of chronic inflammatory diseases although the mechanisms of action remain poorly understood. Emerging explorations of gut microbiotaherb interactions provide a potential to revolutionize the way we view herbal therapeutics. This review summarizes the experimental studies performed on animals and humans regarding the gut microbiota-herb interactions targeting obesity. This review also discusses the opportunity of herbs with potent activities but low oral bioavailability conundrum for prevention and therapy for obesity and related cardiovascular disease.
Keywords: Obesity, cardiovascular disease, gut microbiota, oral availability conundrum, gut microbiota-herb interactions, microbiota availability.
Current Pharmaceutical Design
Title:Targeting Obesity for the Prevention of Chronic Cardiovascular Disease Through Gut Microbiota-Herb Interactions: An Opportunity for Traditional Herbs
Volume: 23 Issue: 8
Author(s): Feng Chen, Jun Jiang*, Dan-Dan Tian, Qi Wen, Yong-Hui Li, Jun-Qing Zhang, Chen Cheng and Tengfei Wang*
Affiliation:
- Hainan Medical College, 3 Xueyuan Road, Haikou 571199,China
- Department of Pharmacology, University of Tennessee Health Science Center, Memphis, TN 38163,United States
Keywords: Obesity, cardiovascular disease, gut microbiota, oral availability conundrum, gut microbiota-herb interactions, microbiota availability.
Abstract: Cardiovascular disease still remains the primary cause of death worldwide and obesity is becoming recognized as one of the most critical contributing risk factors. The increased prevalence of obesity casts a cloud over the global health and the whole societies and will still be burdened in the future. Therefore, prevention and therapy of obesity is a beneficial strategy for the prevention of chronic cardiovascular disease. Numerous studies have demonstrated that gut microbiota takes part in human health and disease including obesity. Traditional herbs hold great potential to improve people’s health and wellness, particularly in the area of chronic inflammatory diseases although the mechanisms of action remain poorly understood. Emerging explorations of gut microbiotaherb interactions provide a potential to revolutionize the way we view herbal therapeutics. This review summarizes the experimental studies performed on animals and humans regarding the gut microbiota-herb interactions targeting obesity. This review also discusses the opportunity of herbs with potent activities but low oral bioavailability conundrum for prevention and therapy for obesity and related cardiovascular disease.
Export Options
About this article
Cite this article as:
Chen Feng, Jiang Jun*, Tian Dan-Dan, Wen Qi, Li Yong-Hui, Zhang Jun-Qing, Cheng Chen and Wang Tengfei*, Targeting Obesity for the Prevention of Chronic Cardiovascular Disease Through Gut Microbiota-Herb Interactions: An Opportunity for Traditional Herbs, Current Pharmaceutical Design 2017; 23 (8) . https://dx.doi.org/10.2174/1381612822666161014115724
DOI https://dx.doi.org/10.2174/1381612822666161014115724 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Telmisartan in the Management of Diabetic Nephropathy: A Contemporary View
Current Diabetes Reviews OPA1 in Cardiovascular Health and Disease
Current Drug Targets Antioxidant Food Supplements and Obesity-Related Inflammation
Current Medicinal Chemistry In vitro Anti-glycation and Anti-oxidant Properties of Synthesized Schiff Bases
Medicinal Chemistry High Glucose Affects the Cytotoxic Potential of Rapamycin, Metformin and Hydrogen Peroxide in Cultured Human Mesenchymal Stem Cells
Current Molecular Medicine The Role of Signaling Pathway in the Biological Cause of Rheumatoid Arthritis
Current Drug Research Reviews Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors
Current Pharmaceutical Design Nuclear Factor Erythroid 2 - Related Factor 2 Signaling in Parkinson Disease: A Promising Multi Therapeutic Target Against Oxidative Stress, Neuroinflammation and Cell Death
CNS & Neurological Disorders - Drug Targets Mimicking Microvascular Alterations of Human Diabetic Retinopathy: A Challenge for the Mouse Models
Current Medicinal Chemistry Therapeutic Strategies for Treatment of Inflammation-related Depression
Current Neuropharmacology Brain Protection and Cognitive Function: Cocoa Flavonoids as Nutraceuticals
Current Pharmaceutical Design Multiple Lipid-lowering Treatment in Pediatric Patients with Hyperlipidemia
Medicinal Chemistry Healthy Properties of Garlic
Current Nutrition & Food Science Environmental Chemicals and Breast Cancer Risk – A Structural Chemistry Perspective
Current Medicinal Chemistry The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets Inflammatory Responses in Brain Ischemia
Current Medicinal Chemistry Pulmonary Drug Delivery System: A Novel Approach for Drug Delivery
Current Drug Therapy Management of Cardiovascular Risk Factors in Patients with Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients
Current Vascular Pharmacology Elucidation of Structural Requirements of Mastoparan for Mast Cell Activation- Toward the Comprehensive Prediction of Cryptides Acting on Mast Cells
Protein & Peptide Letters